Post SARS-CoV2 study: Ruconest
Official title Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens
ClinicalTrials.gov ID: NCT07932002
What this study is testing
What is Ruconest?
Ruconest is an investigational medicine, given as an IV infusion (through a vein), being studied as a potential treatment for post sars-cov2 (covid-19).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Assessment of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Alleviating Neurological Symptoms Linked to Infectious Pathogens
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- Age 18 and older, male or female
- Patient is able to understand and fully participate in the activities of the study and the consent in accordance with federal regulations.
- Patients who were involved in the previous study with defined post-COVID neurologic symptoms.
- New patients who have been diagnosed with post-COVID neurologic symptoms.
You likely can't join if
- Receiving any form of C1-INH therapy, either acute or prophylactic treatment
- History or suspicion of allergy to rabbits
- Neurological conditions related to injury
- Neuropathy related to diabetes
- Abnormal kidney or liver enzymes
- History of thrombotic stroke
See the full eligibility criteria
- Age 18 and older, male or female
- Patient is able to understand and fully participate in the activities of the study and the consent in accordance with federal regulations.
- Patients who were involved in the previous study with defined post-COVID neurologic symptoms.
- New patients who have been diagnosed with post-COVID neurologic symptoms.
- Receiving any form of C1-INH therapy, either acute or prophylactic treatment
- History or suspicion of allergy to rabbits
- Neurological conditions related to injury
- Neuropathy related to diabetes
- Abnormal kidney or liver enzymes
- History of thrombotic stroke
- Participants who are pregnant or lactating
- Largely incapacitated or bed-ridden
- Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study or have discontinued...
The study team makes the final eligibility decision.
Where it is enrolling
- Centennial, Colorado, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Centennial, Colorado, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.